Loading...
Loading...
Navidea Biopharmaceuticals, Inc. (NYSE MKT:
NAVB) today announced that
results from an investigator-initiated imaging study demonstrated
Lymphoseek® (technetium Tc 99m tilmanocept) injection reduced
imaging time by more than 50% in sentinel lymph node biopsy procedures
in malignant melanoma compared to Tc99m sulfur colloid (SC). This
finding suggests hospitals and oncology treatment teams can achieve
greater patient throughput and workflow efficiencies utilizing
Lymphoseek. Results of the study, conducted at the Thomas Jefferson
University Hospitals and led by Charles M. Intenzo, M.D., Professor of
Radiology, Director, Nuclear Medicine and Molecular Imaging in the
Department of Radiology were presented today at the Radiological Society
of North America Annual Meeting (RSNA 2015) in Chicago, Illinois.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in